221 filings
Page 3 of 12
8-K
tj4erc
29 Mar 22
Departure of Directors or Certain Officers
4:31pm
8-K
1iv 7rsfv2
24 Mar 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
POS AM
c3ooym5je2tay
22 Mar 22
Prospectus update (post-effective amendment)
4:30pm
POSASR
02g1 m0w1
16 Mar 22
Automatic shelf registration (post-effective amendment)
5:21pm
8-K
tdht1b8j9j7
16 Mar 22
Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
5:18pm
8-K
en3yp
22 Feb 22
Athenex Announces Appointment of Chief Financial Officer
4:16pm
8-K
npzdsnlslt2ygzzflp
15 Feb 22
Athenex Announces Completion of Sale of Dunkirk Manufacturing Facility
9:00am
8-K
4vuu1en2pzc2pnp4ig
21 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
iwz4s6fgbdy e3qp
12 Jan 22
Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility
8:36am
8-K
hjg 0qewngahjf
28 Dec 21
Departure of Directors or Certain Officers
4:16pm
8-K
qykl0ykbrj6kfp0
4 Nov 21
Athenex Provides Third Quarter 2021 Corporate and Financial Update
7:05am
8-K
aavvwl26jf
12 Oct 21
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer
6:31am
8-K
dj3vqk3lk
3 Sep 21
Departure of Directors or Certain Officers
7:16am
8-K
ciod3v4ki77szvv2g3p
20 Aug 21
Entry into a Material Definitive Agreement
5:20pm
424B5
bo56i2j7io
20 Aug 21
Prospectus supplement for primary offering
5:19pm
424B5
lhlh 8mvxisn0rv
16 Aug 21
Prospectus supplement for primary offering
5:27pm
EFFECT
qzfqf5vd4 nenoppodbt
13 Aug 21
Notice of effectiveness
12:15am
CORRESP
q0d09q asmpyz8
10 Aug 21
Correspondence with SEC
12:00am